

Protalix BioTherapeutics, Inc.  
Form 8-K  
September 14, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): September 14, 2009**

**Protalix BioTherapeutics, Inc.**  
**(Exact name of registrant as specified in its charter)**

**Florida**  
**(State or other jurisdiction  
of incorporation)**

**000-33357**  
**(Commission File Number)**

**65-0643773**  
**(IRS Employer  
Identification No.)**

**2 Snunit Street**  
**Science Park, POB 455**  
**Carmiel, Israel**  
**(Address of principal executive offices)**

**20100**  
**(Zip Code)**

**Registrant's telephone number, including area code +972-4-988-9488**  
**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On September 14, 2009, Protalix BioTherapeutics, Inc. (the Company ) issued a press release announcing the completion of its pivotal Phase III trial of prGCD, the Company s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The Company also announced that the proposed brand name for prGCD is UPLYSO . A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated September 14, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: September 14, 2009

By: /s/ David Aviezer

Name:

David Aviezer, Ph.D.

Title: President and Chief Executive Officer

3